Literature DB >> 17581691

[Adrenal incidentalomas].

P Langer1, J Waldmann, M Rothmund.   

Abstract

Adrenal incidentalomas are clinically inapparent masses detected incidentally with imaging studies conducted for other reasons. They are relatively common and require structured diagnostic workup. In many cases surveillance is warranted. The diagnostic workflow has to reveal whether the mass is hormonally functioning and/or if there is evidence of malignancy. If the tumor is functionally silent and not larger than 4 cm, surveillance is warranted. Functioning tumors and masses larger than 6 cm have to be resected. Fine-needle aspiration biopsy is indicated in very rare cases, but pheochromocytoma has to be ruled out first.

Entities:  

Mesh:

Year:  2007        PMID: 17581691     DOI: 10.1007/s00104-007-1365-x

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  45 in total

1.  Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features.

Authors:  R Rossi; L Tauchmanova; A Luciano; M Di Martino; C Battista; L Del Viscovo; V Nuzzo; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

Review 2.  Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course.

Authors:  Teresa M Seccia; Ambrogio Fassina; Gastone G Nussdorfer; Achille C Pessina; Gian Paolo Rossi
Journal:  Endocr Relat Cancer       Date:  2005-03       Impact factor: 5.678

3.  Role for adrenal venous sampling in primary aldosteronism.

Authors:  William F Young; Anthony W Stanson; Geoffrey B Thompson; Clive S Grant; David R Farley; Jon A van Heerden
Journal:  Surgery       Date:  2004-12       Impact factor: 3.982

4.  Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery.

Authors:  Yeşim Erbil; Evin Ademoğlu; Neşe Ozbey; Umut Barbaros; Burcu Tulumoğlu Yanik; Artur Salmaslioğlu; Alp Bozbora; Selçuk Ozarmağan
Journal:  World J Surg       Date:  2006-09       Impact factor: 3.352

5.  Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.

Authors:  C E Fardella; L Mosso; C Gómez-Sánchez; P Cortés; J Soto; L Gómez; M Pinto; A Huete; E Oestreicher; A Foradori; J Montero
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

6.  Results of laparoscopic adrenalectomy for large and potentially malignant tumors.

Authors:  Jean-François Henry; Frederic Sebag; Maurizio Iacobone; Eric Mirallie
Journal:  World J Surg       Date:  2002-06-06       Impact factor: 3.352

7.  Genetic testing in pheochromocytoma or functional paraganglioma.

Authors:  Laurence Amar; Jérôme Bertherat; Eric Baudin; Christiane Ajzenberg; Brigitte Bressac-de Paillerets; Olivier Chabre; Bernard Chamontin; Brigitte Delemer; Sophie Giraud; Arnaud Murat; Patricia Niccoli-Sire; Stéphane Richard; Vincent Rohmer; Jean-Louis Sadoul; Laurence Strompf; Martin Schlumberger; Xavier Bertagna; Pierre-François Plouin; Xavier Jeunemaitre; Anne-Paule Gimenez-Roqueplo
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

8.  A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines.

Authors:  Anna M Sawka; Roman Jaeschke; Ravinder J Singh; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

9.  Endosonographic imaging of benign and malignant pheochromocytomas.

Authors:  P H Kann; B Wirkus; T Behr; K-J Klose; S Meyer
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

Review 10.  Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas.

Authors:  J E Lee; D B Evans; R C Hickey; S I Sherman; R F Gagel; M C Abbruzzese; J L Abbruzzese
Journal:  Surgery       Date:  1998-12       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.